Elcelyx phase IIb study of NewMet for type 2 diabetes meets primary endpoint

[Northerner]

Elcelyx Therapeutics announced that NewMet, the delayed-release formulation of generic metformin for the treatment of patients with type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo.

http://www.pharmabiz.com/NewsDetails.aspx?aid=77522&sid=2